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ABSTRACT 
The glycated Hemoglobin (HbA1c) test is one of the most important diagnostic 
and prognostic strategies for monitoring diabetes. However, the clinical utility of this test 
is questionable for sickle cell disease patients, who are homozygous for a variant 
hemoglobin gene (HBB). While there have been analyses from individual provider 
organizations, no prior national level analysis of the HbA1c ordering practice for sickle 
cell disease patients has been performed. A national level assessment could serve as a 
baseline to evaluate this quality concern in individual health care settings. The main 
objective of this study was to evaluate the frequency of the inappropriate HbA1c test 
orders and the prevalence of the more appropriate fructosamine test orders as an 
alternative to HbA1c test, nationally and at Truman Medical Center (TMC) in Kansas 
City, MO. We analyzed de-identified, HIPAA compliant, electronic health record (EHR) 
data in the Cerner Health Facts ™ (HF) data warehouse. We identified the frequency of 
inappropriate orders of HbA1c tests by comparing the 526 Sickle cell patients in TMC 
with 36,625 sickle cell patients from 393 national facilities in the data warehouse. The 
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linear unbiased percentages estimated from the Generalized Linear Mixed Model 
(GLMM) was used to rank the TMC with other national hospitals based on the 
percentage of sickle cell patients with inappropriate HbA1c test. TMC had a significantly 
higher percentage of sickle cell patients with HbA1c tests when compared to the national 
hospital cohort (32% versus 11%). The results showed that TMC ranks in the bottom 
25% quartile of the 393 qualifying facilities with respect to inappropriate HbA1c orders. 
Interestingly, TMC sickle cell patients were ten-fold more likely to have at least one 
fructosamine encounter when compared to the sickle cell patients in the other 10 national 
hospitals which had fructosamine encounters (11% versus 1%). However, there was still 
a significantly higher number of sickle cell disease patients in TMC than in other national 
hospitals who had only HbA1c tests (24% versus 10%). These findings indicate that 
inappropriate HbA1c orders in sickle cell patients is a potential quality concern at TMC 
which can be addressed with sustainable interventions so that overtreatment or under-
treatment of the diabetic condition in sickle cell patients are avoided. 
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CHAPTER 1 
INTRODUCTION 
Sickle cell disease (SCD) is one of the most common severe monogenic 
hematological disorders worldwide. It is a multi-system disease that leads to the 
abnormal structure of the globin chains of the hemoglobin molecule depending on the 
exact mutation in each hemoglobin gene (Kohne, 2011; Weatherall & Clegg, 2001). In 
United States, the sickle gene is present in approximately 8% of the African-American 
population. SCD is estimated to affect 100,000 Americans where it occurs among 1 out 
of every 365 African-American births and among 1 out of every 16,300 Hispanic-
American births (CDC, 2016). The glycated hemoglobin A1c (HbA1c) test measures 
glucose bound to hemoglobin and is used to monitor long term glycemic control and for 
diagnosing diabetes mellitus (Lenters-Westra, Schindhelm, Bilo, & Slingerland, 2013). 
However, the clinical utility of this test is questionable for Sickle cell disease patients. Of 
the estimated 366 million individuals with diabetes mellitus in 2011, around 26 million 
also had a hemoglobin (Hb) disorder (Whiting, Guariguata, Weil, & Shaw, 2011). In this 
study we focus on patients who are homozygous for a variant gene (HbS, HbC, HbE, Hb-
G, Hb-J, Hb-K, Hb-O, Hb-P)(Rees, Williams, & Gladwin, 2010a). In these patients, the 
glycated form of the hemoglobin variant polymerize together leading to erythrocyte 
rigidity and vaso- occlusion. Therefore, these erythrocytes have a shorter lifespan (10-20 
days) compared to a normal erythrocyte (90-120 days)(Kohne, 2011). The presence of 
hemoglobin variants, could affect the net charge of the hemoglobin and the recognition of 
the glycated N terminus by antibodies thereby resulting in erroneous HbA1c values. The 
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hemoglobin variants affect the HbA1c test as it alters the normal process of glycation of 
HbA to A1C which produces an abnormal peak on chromatography, making estimation 
of HbA1C unreliable. As the measurement of HbA1c is dependent on normal erythrocyte 
life span, conditions like abnormal red cell turnover, anemia and blood transfusions may 
also interfere with the validity of HbA1c measurement as it decreases the time for 
glycosylation to occur thereby producing a falsely low A1C result (Lippi & Targher, 
2011; Speeckaert et al., 2014). Therefore, the accuracy of the HbA1c measurement, can 
be adversely affected due to the qualitative and quantitative differences in hemoglobin by 
the presence of these hemoglobin variants. 
Hemoglobin variants can affect HbA1c levels leading to the use of alternative 
measures for glycemic control that are not based on hemoglobin among these patients 
(Bry, Chen, & Sacks, 2001; Gunton & McElduff, 2000; Schnedl et al., 2000; Smaldone, 
2008; Tran, Silva, & Petrovsky, 2004). The alternative measure of glycemic index 
primarily includes the fructosamine test, glycated albumin test and 1,5,anhydroglucitol. 
However, the latter two tests are not as extensively evaluated in clinical settings as 
fructosamine (Speeckaert et al., 2014). The total concentration of fructosamine is 
predominantly a measure of glycated albumin and a minor contribution of other 
circulatory proteins such as glycated lipoproteins and glycated globulins (Cohen, Holmes, 
Chenier, & Joiner, 2003). Several studies have established cut-offs and correlations to 
glucose and HbA1c confirming that fructosamine test is a useful indicator of 
hyperglycemia (Baker, Metcalf, Holdaway, & Johnson, 1985; Baker, Metcalf, Johnson, 
Newman, & Rietz, 1985; Baker, O’Connor, Metcalf, Lawson, & Johnson, 1983; Cohen et 
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al., 2003; Juraschek, Steffes, & Selvin, 2012; Ko et al., 1998; Malmström et al., 2014; 
Selvin et al., 2014). Accordingly, the measurement of fructosamine either as a standalone 
indicator of hyperglycemia or in combination with glucose and HbA1c would potentially 
be a useful tool in conditions in which HbA1c is unreliable.  
As such, inappropriate use of HbA1c as a standalone test for Sickle cell disease 
patients to diagnose or screen diabetes is a major quality concern in health care as it 
might lead to overtreatment or under-treatment of the diabetic condition in these patients. 
Sustainable interventions such as the assessment of other indices of chronic glycemia are 
recommended for these patients (Juraschek et al., 2012). While there have been analyses 
from individual provider organizations (Atabani et al., 1989; Reid et al., 1992; Weykamp 
et al., 1993; Lacy et al., 2017), no prior national level assessment of this ordering practice 
has been performed. This national level assessment could serve as a baseline to evaluate 
this quality concern in individual health care settings.  
Electronic Health Records (EHR) are a comprehensive, cross-institutional and 
longitudinal collection of patient’s health care data (Hoerbst & Ammenwerth, 2010). 
Several studies have demonstrated that EHR systems promote cost-effective and 
sustainable solutions for improving quality in medical care (Hillestad et al., 2005; 
Johnston, Langton, Haynes, & Mathieu, 1994; Wang et al., 2003). Access to data derived 
from the EHR in multi-institutional data warehouses provide a powerful resource for 
national level assessment, to compare practices and outcomes across independent, non-
affiliated, organizations to guide and identify quality improvement initiatives. Any public 
health challenge concern requires joint effort from academic researchers in collaboration 
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with clinical and public health practitioners, to identify quality gaps and to implement 
sustainable interventions (Ammerman, Smith, & Calancie, 2014). This approach, known 
as Practice Based Evidence (PBE), is an integral aspect of the Institute of Medicine 
(IOM) Learning Healthcare System strategy and can be performed by analyzing data 
generated during the delivery of the patient care (Smith, Halvorson, & Kaplan, 2012). 
This approach is different from the Evidence-based medicine (EBM) approach which 
requires systematic review of the published literature, engagement of experts on the topic 
and abstraction and reconciliation of knowledge from disparate sources. The PBE 
approach overcomes the challenges of EBM which include frequent gaps in the literature 
(including the literature related to laboratory quality improvement), limited resources to 
support the engagement of a panel of experts and the lengthy time required to complete a 
comprehensive EBM analysis. Often quality improvement (QI) projects are selected in 
reaction to a recent adverse event. While this is frequently necessary after a critical issue, 
it may also result in failure to recognize deeper systemic quality gaps in which an 
organization is at significant variance from their peers. With respect to laboratory quality 
improvement, there is a significant opportunity to apply the PBE strategy to the 
recognition of quality gaps, the selection of critical quality improvement projects and 
comparison with facilities with a high and low frequencies of the quality gap in order to 
inform interventions (Green, 2008). 
This study utilized a Practice Based Evidence approach by analyzing a de-
identified, HIPAA compliant, electronic health record (EHR) data in the Cerner Health 
Facts ™ (HF) national data warehouse. Truman Medical Centers (TMC), Kansas City, 
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MO, is a contributor to this national data warehouse. This was implemented by 
quantifying the frequency of Sickle cell patients with inappropriate HbA1c orders and the 
prevalence of fructosamine orders in TMC and by comparing this ordering practice 
across other independent, non-affiliated organizations in the national data warehouse. The 
present analysis of this large clinical national data warehouse was undertaken to guide 
TMC in identifying and evaluating this potential quality concern.  
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CHAPTER 2 
REVIEW OF LITERATURE 
Sickle cell Disease 
Sickle cell disease (SCD) is a collection of blood-disorders which occurs when a 
person inherits two abnormal copies of the hemoglobin gene, one from each parent (Rees, 
Williams, & Gladwin, 2010b). There are more than 1300 known hemoglobin variants, 
with the majority of them rare in prevalence while some reach high frequencies in 
specific population groups (Patrinos, G.P., B. Giardine, C. Riemer, W. Miller, D.H.K. 
Chui, N.P. Anagnou, H. Wajcman, and R.C. Hardison, 2004). The most common type is 
the Sickle cell anemia (homozygous HbSS) which results due to the inheritance of 
Glu6Val mutation in the HBB gene from both parents and permits the formation of the 
pathological sickle hemoglobin tetramer(Ware, Montalembert, Tshilolo, & Abboud, 
2017). This abnormal mutant hemoglobin S, undergoes intracellular polymerization and 
feature the propensity of erythrocytes to stick together and form long molecules by 
stretching the normal flexible biconcave shape into sickle shape cells on deoxygenation. 
These sickle-shaped cells are rigid and can die prematurely, blocking small blood vessels 
and causing vaso-occlusion. This can lead to anemia, severe pain, infection, infarction, 
acute illness and progressive chronic organ complications, including cardiopulmonary, 
renal and vascular dysfunction (Elmariah et al., 2014; Powars, Chan, Hiti, Ramicone, & 
Johnson, 2005). The diagnosis of Sickle cell disease is relatively simple, using techniques 
such as electrophoresis which separate normal from variant hemoglobin using standard 
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alkaline gel, isoelectric focusing, capillary electrophoresis or high performance liquid 
chromatography (Ware et al., 2017).  
According to a published estimate, in 2010 there were 312,302 newborns born 
with Sickle cell anemia and over half of them were born in Africa, India, Eastern 
Mediterranean and Middle East (Piel et al., 2013). The 2015 Global Burden of Disease 
report includes Sickle cell disease as causing more than 100,000 deaths which represents 
a 6% increase in prevalence since 2005 (Global Burden of Disease Study 2013 
Collaborators, 2015). Individuals with Sickle cell trait, (heterozygous HbAS) have some 
resistance to the often fatal malaria, a likely explanation for the persistence and the 
distribution of the sickle gene in the malaria-endemic tropic and sub-tropic areas (Piel et 
al., 2010). Even though Sickle cell disease were originally characteristic of the tropics 
and the sub-tropics, they are now encountered world-wide due to migrations of 
population (Weatherall & Clegg, 2001).  
Hemoglobin A1c Test 
Diabetes mellitus is a frequent disorder affecting individuals of all ages. 
Glycohemoglobin has a key role in the assessment of glycemic control in diabetic 
patients. Glycated hemoglobin is hemoglobin that has been irreversibly modified by 
addition of a glucose through a non-enzymatic process and provides a weighted average 
of plasma glucose concentration over the erythrocyte lifespan (Camargo & Gross, 2004). 
It has a key role in the assessment of glycemic control which is strongly associated with 
development and progression of diabetic complications in both type 1 and 2 diabetes 
mellitus. In the presence of excess plasma glucose, the hemoglobin beta-chain becomes 
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increasingly glycosylated, making the A1C a useful index of glycemic control in patients 
with diabetes mellitus (Kawano, 1999). Normally in most individuals, Hb consists of 
~97% HbA, <2.5% HbA2 and 0.5% HbF (Sacks, 2012). In healthy individuals, 6% of the 
HbA is glycated to form HbA1a, HbA1b and HbA1c (Lenters-Westra et al., 2013). 
HbA1c results from the attachment of a glucose molecule to the N-terminal valine of the 
Hb β-globin chain and the rate of HbA1c production is directly proportional to the 
ambient glucose concentration (Bry et al., 2001). This has been expressed as a ratio 
(HbA1c/total Hb) in order to compensate for intra- and interindividual variation in the 
total Hb concentration (C. Weykamp, John, & Mosca, 2009). The long life-span of 
erythrocytes (On average, 117 days in men and 106 days in women) enable the 
measurement of HbA1c to be used as an index of glycemic control over the preceding 
two to three months and correlate well with the risk for the development of chronic 
complications related to diabetes (Jeffcoate, 2004). The current diagnostic criteria for the 
diagnosis of diabetes as published by the American Diabetes Association (ADA) is based 
on the HbA1c value >6.5% (ie, > 48 mmol/mol), while an increased risk of diabetes (ie, 
prediabetes) is based on the HbA1c value 5.7 - 6.4% (ie, 39–46 mmol/mol) (American 
Diabetes Association, 2014). 
The HbA1c test is not foolproof and some of the well-recognized drawbacks 
include lower diagnostic efficiency in specific populations (pregnant women, elderly and 
non-Hispanic blacks) or end-stage renal disease or heavy alcohol consumption; risk of 
over-diagnosing diabetes in presence of iron deficiency anemia or Vitamin B12 
deficiency or rheumatoid arthritis or in cases of certain hemoglobinopathies (El-Agouza, 
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Abu Shahla, & Sirdah, 2002; Jiao, Okumiya, Saibara, Park, & Sasaki, 1998; Lippi & 
Targher, 2010; Uzu et al., 2009). One of the major factors that affect the accuracy of 
HbA1c measurements depends on the assay method and the specific hemoglobin variant. 
There are two forms of glycated Hb in heterozygous individuals carrying HbA and the 
variant Hb gene (HbAS, HbAE, HbAC etc). This may result in the deviation of HbA1c 
which may lead to over- or under-treatment of diabetic patients (Lacy et al., 2017). 
Extensive work has been done by the NGSP (National Glycohemoglobin Standardization 
Program) to standardize the appropriate methods that can be used to measure HbA1c 
even in the presence of hemoglobin variants (NGSP: Factors that Interfere with HbA1c 
Test Results, 2014.). ADA has acknowledged that in patients with Sickle cell disease, for 
whom HbA1c is unreliable due to the altered red cell turnover, the assessment of other 
indices of chronic glycemia may be advisable. These alternative measures include 
fructosamine and glycated albumin (GA).  
Fructosamine Test 
Fructosamine (1-amino-1-deoxy-D-fructose) represents a clinically accessible 
measure of non-enzymatic glycation of proteins in the same compartment as plasma 
glucose and should integrate plasma glucose fluctuations. The total concentration of 
fructosamine is a measure of glycated albumin, along with the contribution of other 
circulatory proteins such as glycated lipoproteins and glycated globulins (Cohen et al., 
2003). It is a simple, robust and inexpensive biomarker that gives an earlier indication of 
poorly controlled glucose compared to HbA1c for diabetic patients (True, 2009). 
However, as the half-life of non-immunoglobin serum proteins is much lower (~14-21 
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days) compared to red blood cells (~90 to 120 days), this means that fructosamine 
provides a short term glycemic control (previous two weeks) compared to HbA1c test 
which provides a long term glycemic control (over a period of 2-3 months)(Roohk & 
Zaidi, 2008). Another important difference is that the rate of non-enzymatic glycation of 
the proteins are 9-10 fold higher than hemoglobin. As a consequence, the blood levels of 
fructosamine exhibit a broader fluctuation than those of HbA1c (Rondeau & Bourdon, 
2011).  
Electronic Health Records  
Electronic Health records (EHR) have been shown to coordinate care, routinely 
measure quality or reduce medical errors. This can facilitate workflow and improve the 
quality of patient care which can provide substantial benefits to physicians, clinics and 
health care organizations (Elson & Connelly, 1995). The implementation of the 
"meaningful use" criteria for EHR, mandated by the Health Information Technology for 
Economic and Clinical Health (HITECH) Act of 2009 has committed unprecedented 
resources to supporting the adoption and use of EHRs. The HITECH legislation further 
required that meaningful use include electronic reporting of data on the quality of care. 
This funding will provide important support to achieve liftoff for the creation of a 
nationwide system of EHRs (Blumenthal & Tavenner, 2010).  However, analyses of 
electronic health record (EHR) data, is challenging as it contains valuable yet 
heterogenous and complex data in terms of missing values, inconsistent records and high 
dimensionality (Miller & Sim, 2004). As it is not possible to control the circumstances 
under which the measurements are taken in the EHR, there may be considerable variation 
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in the observations due to the differences in practice, policy and personnel in different 
facilities. The data is uncorrelated as it is drawn from a hierarchy of different populations 
These observations also exhibit dependency as measurements of different attributes are 
taken from the same patient over time.   
In this study we have used a multi-institutional national data warehouse to 
identify and quantify a potential quality concern in the Truman Medical Centers (TMC) 
by comparing the mis-utilization of HbA1c orders in Sickle cell disease patients with 
other national hospitals. TMC are the primary safety net facilities for Jackson County 
MO area which consist of two hospitals totaling 600 beds, outpatient clinics and a 
behavioral health center. The Hospital Hill campus of TMC serves the urban core of 
Kansas City, Missouri and provides 249 acute, 52 Emergency Department bed hospital, a 
Level One trauma center, a Level Three NICU and a dedicated Sickle cell disease center. 
The Lakewood campus serves the eastern suburbs of Jackson, County Missouri.  
The main objective of the present study was to evaluate the inappropriate HbA1c 
test orders for Sickle cell patients as a major quality concern by implementing the 
practice based evidence model using the national data warehouse, Health Facts database 
(Cerner Corporation, Kansas City, MO). This study also ranks TMC with other national 
hospitals in terms of its percentage of Sickle cell patients by implementing the 
Generalized Linear Mixed Model. An additional objective was to evaluate the utilization 
of the fructosamine test for Sickle cell patients relative to the HbA1c test in TMC 
compared to other national hospitals.  
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CHAPTER 3 
METHODOLOGY 
Data Source 
This study uses the Health Facts database (Cerner Corporation, Kansas City, 
MO), a national data warehouse that collects comprehensive clinical records across 
healthcare facilities throughout the United States. Health Facts is a voluntary program 
offered to organizations using the Cerner Electronic Health Record (EHR). The database 
contains data systematically extracted from participating institution’s EHR and includes 
encounter data (emergency, outpatient, and inpatient), patient demographics (age, sex, 
and race), diagnoses and in-hospital procedures documented by ICD-9-CM and ICD-10-
CM codes, laboratory data documented by LOINC codes and facility characteristics 
(census region, number of beds, acute setting and teaching versus nonteaching status). 
This comprises of about 5.1 billion encounters (clinical care events) from 64 million 
patients in 863 healthcare facilities. All admissions, medication orders and dispensing, 
laboratory orders and specimens are date and time stamped, providing a temporal 
relationship between treatment patterns and clinical information. All data were 
deidentified in compliance with the Health Insurance Portability and Accountability Act 
(HIPAA) of 1996 before being provided to the investigators. Longitudinal connection 
between  patient encounters within the same health system is preserved (Strack et al., 
2014). 
. 
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Study Cohort 
We conducted a retrospective analysis of patients admitted to the hospital with 
Sickle cell disease between January 2010 and December 2016. Of the 863 facilities in 
Health Facts, 393 had a qualifying Sickle cell population. We included all patients with a 
diagnosis of Sickle cell disease using International Classification of Diseases, Ninth 
Revision and Tenth Revision, Clinical Modification codes (ICD-9-CM and ICD-10-CM). 
The codes were selected based on clinical judgement and in combination with an existing 
published study to identify Sickle cell disease cohort within electronic health records 
using ICD-9-CM diagnosis codes (Michalik, Taylor, & Panepinto, 2017). The phenotypes 
were further validated using PheKB resource. The Phenotype Knowledgebase website 
(PheKB) is a collaborative environment to build and validate electronic algorithms that 
can identify characteristics of patients within health data.  It has tools that can view 
existing algorithms, create and validate new algorithms, collaborate with others to create 
or review algorithms and view implementation details for existing algorithms (Kirby et 
al., 2016). The resulting definition groups (from ICD-9-CM codes) were combined with 
the appropriate ICD-10-CM codes to identify the Sickle cell disease patient cohort (Table 
1). This data represents integrated delivery networks throughout the United States: 
Midwest (79 hospitals), Northeast (68 hospitals), South (162 hospitals), and West (84 
hospitals). Most of the hospitals (239 hospitals) have bed size less than 100, 133 hospitals 
have bed size between 100 to 500 and bed size of 21 hospitals is greater than 500.  
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Table 1. The ICD-9 and ICD-10 CM codes used in this study to identify the Sickle cell 
population which are grouped together based on consensus definition from PheKB 
resource 
 
Definition ICD -9 CM Codes ICD-10 CM 
Codes 
Sickle cell thalassemia without crisis 282.41 
 
D57.4 
D57.40 
Sickle cell thalassemia with crisis 282.42 
 
D57.41 
D57.411 
D57.412 
D57.419 
HbSS disease unspecified 282.6 
282.60 
D57 
HbSS disease without crisis 282.61 D57.1 
HbSS disease with crisis 282.62 D57.0 
D57.01 
D57.02 
Sickle cell/HbC disease without 
crisis 
282.63 
 
D57.20 
Sickle cell/HbC disease with crisis 282.64 
 
D57.2 
D57.21 
D57.211 
D57.212 
D57.219 
Other Sickle cell disease without 
crisis (Hb-D) (Hb-E) (Hb-G) (Hb-J) 
(Hb-K) (Hb-O) (Hb-P) 
282.68 
 
D57.8 
D57.80 
Other Sickle cell disease with crisis 
(Hb-D) (Hb-E) (Hb-G) (Hb-J) (Hb-
K) (Hb-O) (Hb-P) 
282.69 
 
D57.81 
D57.811 
D57.812 
D57.819 
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The majority of the hospitals (300 hospitals) are urban while 93 hospitals are 
rural. As this data represents integrated delivery network health systems in addition to 
stand-alone hospitals, the data contains both inpatient and outpatient data, including 
emergency department, for the same group of patients. 
Extraction of Initial Data from the Database 
The data was initially extracted from the Health Facts database for all encounters 
that had a diagnosis of Sickle cell disease (using the ICD-9-CM and ICD-10-CM codes) 
between 2010 and 2016. This Sickle cell-patient cohort was further analyzed for HbA1c 
encounters based on the criteria that it included all patients with a HbA1c test order 
(identified by LOINC codes: 55454-3, 41995-2, 4548-4, 17855-8, 4549-2, 17856-6) after 
the diagnosis of Sickle cell disease. The Sickle cell patient cohort was also analyzed for 
fructosamine encounters based on the criteria that it included all patients with a 
fructosamine test (identified by LOINC codes: 33805-3, 15069-8, 53550-0) after the 
diagnosis of Sickle cell disease. HbA1c and Fructosamine encounters before 2010 and 
after 2016 were excluded from the analysis in order to avoid data partial in nature.  
Analysis 
The unit of our analysis are the sickle cell patients with at least one HbA1c or 
Fructosamine encounter after the presence of a sickle cell diagnosis. For example, a 
sickle cell patient will be tagged with HbA1c in a year, if the patient had at least one 
HbA1c encounter in that particular year. The baseline demographic characteristics and 
sickle cell diagnosis groups were compared between the sickle cell patients in TMC and 
other national hospitals. Based on the patient population from the sickle cell-A1c dataset, 
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we considered two groups of encounters: (i) no HbA1c test ordered for a sickle cell 
patient after sickle cell diagnosis in TMC compared to all the facilities, (ii) HbA1c test 
ordered for a sickle cell patient after sickle cell diagnosis in TMC compared to all the 
facilities. The latter group represents potentially inappropriate ordering of HbA1c test. 
Based on the patient population from the sickle cell-fructosamine dataset, we 
considered two groups of encounters: (i) no Fructosamine test ordered for a sickle cell 
patient after sickle cell diagnosis in TMC compared to all the facilities, (ii) Fructosamine 
test ordered for a sickle cell patient after sickle cell diagnosis in TMC compared to all the 
facilities. These fructosamine encounters were further analyzed in relation to A1c 
encounters in TMC compared to other national hospitals where we considered the 
following three groups (i) Sickle cell patients with only A1c encounters (ii) Sickle cell 
patients with only fructosamine encounters and (iii) Sickle cell patients with both HbA1c 
and Fructosmine encounters. The latter group was further analyzed to evaluate the 
ordering pattern of A1c orders relative to Fructosamine in TMC compared to other 
national hospitals. 
In order to identify if TMC is ranked lower compared to the other national 
hospitals for the inappropriate orders of HbA1c tests for sickle cell patients and to 
account for the random effects inherent within this diverse dataset and the bias from 
possible covariates, the Generalized Linear Mixed Model (GLMM) was implemented to 
estimate the best linear unbiased predictors as percent ordered for every hospital at each 
year. A generalized linear mixed model is a statistical model that extends the class of 
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generalized linear models by incorporating normally distributed random effects 
(Schabenberger, 2005). 
 The percent of sickle cell patients with HbA1c test orders was taken as the 
outcome variable. Hospital level demographic information such as, census region 
classification, teaching facility or not, urban/ rural location, acute setting and bed size 
were included in the model to account for possible bias. The number of sickle patients 
were also included in the model to account for the different number of sickle patients 
observed at each facility. The PROC GLIMMIX procedure in SAS was used with link 
function equals to logit for proportion outcome (Schabenberger, 2005). Using this model, 
hospital-specific linear unbiased percentage were generated.  This represents the 
percentage of sickle cell disease patients with HbA1c orders in each hospital at each year. 
The estimated percentages for every hospital were ranked to identify the distribution of 
TMC in a quartile. The analysis was performed in SAS statistical software. Graphics 
from R language was used to interpret the ranking of the percentages into quartiles.  
Ethical and Legal Issues  
This research is based on a pre-existing HIPAA compliant dataset that contains no 
personally identifiable information. The UMKC Institutional Review Board has 
determined that all work with Health Facts is considered “non human subjects” research. 
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CHAPTER 3 
RESULTS 
Baseline Characteristics of Sickle cell Patients 
          We initially identified a total of 329,525 encounters for 41,105 sickle cell patients 
of which 9,979 encounters were HbA1c test orders and 296 encounters were 
fructosamine test orders. After the exclusion of HbA1c and Fructosamine encounters 
before 2010 and after 2016, we narrowed down the resulting patient cohort to 37151 
sickle cell patients of which 526 patients were in TMC (Figure 1). The baseline 
characteristics of the Sickle cell patients in TMC were similar to the total sickle cell 
population from all 393 hospitals (Table 2). When the sickle cell patients were distributed 
based on their diagnosis codes (Table 1), 31032 patients were found to be homozygous 
HbSS (unspecified, with and without crisis) which represents 83.53% of the entire sickle 
cell disease population. TMC had a similar profile where 389 patients were homozygous 
HbSS (unspecified, with and without crisis) which represents 74% of the entire sickle cell 
disease population. There was a statistically significant association between TMC and the 
National Hospitals in the case of sickle cell population in the groups of HbSS disease 
unspecified, HbSS disease without crisis, HbSS disease with crisis, sickle cell/HbC 
disease without crisis and other sickle cell disease with crisis where p<0.005. However, 
TMC & the national hospitals were independent of each other in the case of the 
remaining four sickle cell diagnosis groups where p>0.05 (Figure 2). 
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Figure 1. Analysis plan which includes the frequency of the study cohort before and after 
the exclusion criteria 
  
Total Sites = 405 
Total Sickle cell Patients= 41015 
All Encounters = 329525 
A1C Encounters= 9979 
Non-A1C Encounters = 319546 
Fructosamine Encounters= 296 
TMC 
Sickle cell Patients= 527 
All Encounters = 15775 
A1C Encounters= 367 
Non-A1C Encounters = 15408 
Fructosamine Encounters= 128 
TMC 
Total Sickle cell Patients= 526 
All Encounters = 15765 
A1C Encounters= 366 
Non-A1C Encounters = 15399 
Fructosamine Encounters= 128 
Total Sites = 393 
Total Sickle cell Patients= 37151 
All Encounters = 283777
A1C Encounters= 9210 
Non-A1C Encounters = 274567 
Fructosamine Encounters= 288 
2010 < Data > 
2016 are 
Excluded 
Generalized linear mixed Model to predict the percent of sickle cell patients with 
inappropriate HbA1c orders using hospital level information and the number of 
sickle cell patients as covariates.  
Excluded population  
Total Sites = 12 
Total Sickle cell Patients= 3864 
All Encounters = 45748
A1C Encounters= 769 
Non-A1C Encounters = 44979 
Fructosamine Encounters= 8 
All encounters that had a primary diagnosis of Sickle cell disease based on ICD-9-
CM codes and ICD-10-CM codes 
These encounters were evaluated based on the presence of HbA1c encounter or 
fructosamine encounter (identified by LOINC codes) after the diagnosis of Sickle 
cell disease 
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Table 2: The baseline characteristics of the sickle cell patients from the 393 national 
facilities compared to the sickle cell patients in TMC 
 
 
 
 
Baseline Characteristics All 393 Sites TMC 
Age, years (mean) 32.03 years 36.34 
Gender  
Male  
Female 
 
16234 (43.81%) 
20822 (56.19%) 
 
208 (39.54%) 
318 (60.46%) 
Race 
African American 
Asian/Pacific 
Islander 
Biracial 
Caucasian 
Hispanic  
Mid-Eastern 
Indian 
Native American 
Other 
 
23814 (64.10%) 
393 (1.06%) 
73 (0.19%) 
8948 (24.08%) 
142 (0.38%) 
3 (0.01%) 
77 (0.21%) 
2304 (6.2%) 
1370 (3.68%) 
27 (0.07%) 
 
456 (86.69%) 
4 (0.76%) 
 
31 (5.89%) 
1 (0.19%) 
 
 
29 (5.51%) 
5 (0.95%) 
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Figure 2. Percentage distribution of Sickle cell patients based on their type of Sickle cell 
diagnosis in TMC compared to other national facilities. Red * indicates statistically 
significant groups 
 
 
HbA1c Encounters in Sickle Cell Population  
When the sickle cell patient cohort was analyzed for HbA1c encounters after the 
diagnosis of sickle cell disease, 11% of the total Sickle cell population (3,927 patients) 
had at least one HbA1c encounter (Figure 3). However, at TMC 170 patients, almost 32% 
of the sickle cell population in TMC, had at least one HbA1c encounter (Figure 3). This 
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shows that the sickle cell population in TMC is tested by HbA1c much more often than 
compared to their peers. When we broke this down to the annual rate of HbA1c 
encounters, the sickle cell population in TMC with HbA1c encounters was consistently 
higher every year when compared to the other national facilities (Figure 4). 
 
 
 
Figure 3. HbA1c encounters of sickle cell patients at all 393 hospitals compared to TMC 
3927
11%
33224
89%
All 393 Facilities
Atleast one A1C Encounters No A1c Encunters
170
32%
356
68%
TMC
Atleast one A1C Encounters No A1c Encunters
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Figure 4. Sickle cell patients with HbA1c encounters per year from 2010 to 2016 at all 
393 hospitals compared to TMC 
 
 
Ranking TMC among other National Facilities 
We used the generalized Linear mixed model to rank both the hospitals of TMC 
(Hospital Hill and Lakewood) against the other national hospitals for the recent years 
from 2014-2016. Here, each rank of the hospital is calculated based on the ratio of the 
percentage of HbA1c test ordered for each sickle cell patient per year. From this model 
(Figure 5), it can be observed that TMC Hospital hill is above the 75% cut-off, and TMC 
Lakewood is almost near the 75% cut-off mark for all the three years and that both the 
hospitals are in the bottom 25% quartile with respect to the percentage of inappropriate 
HbA1c tests when compared to all the other national hospitals. This indicates that this is a 
potential quality concern which needs to be addressed with sustainable interventions.  
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Figure 5. Ranking TMC against other national hospitals based on the linear unbiased 
predicted percentages from the generalized linear mixed model. Each bar represents one 
site in that year (Red bar indicates: LW – TMC Lakewood and HH- TMC Hospital Hill) 
LW 
LW 
LW 
HH 
HH 
HH 
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Fructosamine Encounters in Sickle cell Population 
In order to consider whether there were indications of a shift in practice toward 
more appropriate test ordering, we screened the encounters from the sickle cell cohort for 
fructosamine orders and found an interesting perspective of the data. There were just 288 
Fructosamine encounters in the entire sickle cell population cohort of which 44% of those 
encounters (128 Fructosamine encounters) were from TMC. There were only 11 hospitals 
from the sickle cell cohort which had fructosamine encounters and these facilities had 
7502 sickle cell patients of which TMC includes 526 sickle cell patients. Excluding 
TMC, the remaining 10 hospitals have 74 sickle cell patients who had at least one 
fructosamine encounter while TMC has 10 fold higher sickle cell patient ratio (60 
patients) who had at least one fructosamine encounter (Figure 6).  
We further mapped out those 134 patients (TMC and the national hospitals) with 
fructosamine encounters and their hospitals based on their region and compared it with 
patients with HbA1c encounters in that particular region (Figure 7). From this we can 
observe that from the entire sickle cell population in the Midwest region (4441 patients) 
around 20% of them had HbA1c encounters which is almost the same as in the North 
(29%) and Northeast region (21%). However, the midwest region is the only region 
where ~2% of sickle cell patients had fructosamine encounters while the rest of the sickle 
cell population in other regions had very few to no fructosamine encounters.  
In order to further investigate the reason behind the high frequency of both 
HbA1c encounters and Fructosamine encounters in TMC compared to the other national 
hospitals, we decided to further analyze these 6450 patients in the 10 other national 
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hospitals where some of them must have both HbA1c and Fructosamine orders. 
Analyzing the relative order percentage of each test shows that the other 10 hospitals 
(excluding TMC) have about 3802 sickle cell patients who had either one of those two 
tests or both. While 98% of those patients had only HbA1c test, 1% had both 
fructosamine and HbA1c test and 1% had only Fructosamine test (Figure 8). Whereas in 
TMC, 190 sickle cell patients had either one of those two tests or both and only 68% of 
them had only HbA1c test while 21% of them had both HbA1c and Frutosamine (Figure 
8). This suggests that there might be HbA1c ordering pattern relative to fructosamine test. 
 
 
 
Figure 6. Fructosamine encounters for Sickle cell patients at 10 other national hospitals 
compared with TMC 
74
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6376
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Figure 7.  Sickle cell patients mapped according to their US census region and the 
estimates of their HbA1c orders (red) and Fructosamine orders (green) are given 
respectively for each region 
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Figure 8. Order percentage of only HbA1c Test, Fructosamine test or both HbA1c and 
Fructosamine test in 10 other hospitals compared to TMC 
 
 
              Analyzing the timestamp of all the HbA1c encounters and fructosamine 
encounters associated with the 89 patients (patients in the green subset in Figure 8) who 
had both fructosamine and HbA1c encounters (410 encounters) in the 10 national 
facilities other than TMC shows that 62% of those encounters were HbA1c tests that 
were ordered before the patient was screened with the first fructosamine test and 7% of 
those encounters were HbA1c and fructosamine tests that were ordered together while 
31% of those HbA1c encounters were ordered even after the patients had fructosamine 
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test (Figure 9). In TMC, the 40 patients (patients in the green subset in TMC in Figure 8) 
who had both HbA1c and fructosamine tests were analyzed for the HbA1c ordering 
pattern. It was found that 27% of those 40 patients who had been tested with HbA1c and 
Fructosamine together was almost three-fold higher when compared to the other 10 
national facilities (7% of the sickle cell patients). 
 
 
 
Figure 9: Ordering pattern of HbA1c test relative to Fructosamine test in sickle cell 
population who had both HbA1c test and Fructosamine test in the 10 national facilities 
and in TMC 
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CHAPTER 4 
DISCUSSION 
The measurement of glycosylated HbA1c is widely accepted as the cornerstone of 
diagnosis and management of diabetes. However, this test is unreliable for sickle cell 
disease patients due to their hemoglobin variant and its associated pathological processes 
including anemia, increased red blood cell turnover, transfusion requirements and 
increased HbF (Bry et al., 2001). Corrections to some HPLC and cation-exchange 
methods allow accurate, analytical determination of the glycated hemoglobin in these 
Sickle cell disease patients (C. W. Weykamp, Penders, Siebelder, Muskiet, & Van der 
Slik, 1993), however these values impact HbA1c as a marker of long-term glycemic 
control as the glycated variant hemoglobin has a shorter lifespan. Moreover, there are 
HbA1c methods which do not report results while some methods flag it as abnormal 
peaks (Carta, Dall’Olio, & Soffiati, 1997; John, Braconnier, Miedema, Aulesa, & Piras, 
1997). Several studies indicate falsely lower level HbA1c values for sickle cell 
homozygous patients(Gunton & McElduff, 2000; Malekiani, Ganesan, & Decker, 2008; 
Smaldone, 2008; Tran et al., 2004). Based on these reports, the information campaign and 
physician’s new release sponsored by the National Institute of Diabetes and Digestive 
and Kidney Diseases stressed the importance of avoiding HbA1c test for Sickle cell 
disease patients as it might be unreliable (“Sickle cell Trait & Other Hemoglobinopathies 
& Diabetes (For Providers) | NIDDK,” 2016). The National Glycohemoglobin 
Standardization Program, supported by the National Institute of Diabetes and Digestive 
and Kidney Diseases and Centers for Disease Control and Prevention, has standardized 
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the measurements of HbA1c in laboratories in patients with HbS trait and HbC variant. 
However, for patients with homozygous sickle cell condition, they caution against the use 
of HbA1c test and propose other alternative tests glycated serum protein or glycated 
albumin which can be considered for these patients(“NGSP: Factors that Interfere with 
HbA1c Test Results,” 2016). Based on these two reports, The Center for Disease Control 
and Prevention had also released information for providers to not use HbA1c test for 
Sickle cell trait patients and other hemoglobinopathies as it might falsely lower HbA1c 
values(CDC, 2017). Futhermore, ADA has acknowledged that in patients with Sickle cell 
disease, in whom HbA1c is unreliable due to the altered red cell turnover, the assessment 
of other indices of chronic glycemia may be advisable(ADA, 2014).  
The prior reports provided local analysis of this ordering practice. However, there 
has been no national level analysis to set a baseline characteristic of inappropriate HbA1c 
orders for sickle cell disease patients. Our work is unique in that we have a population 
wide look for this ordering practice using HIPAA compliant, de-identified national data 
warehouse, Cerner’s Health Facts database. And, used this as a baseline in evaluating this 
quality concern of inappropriate HbA1c orders in Truman Medical Centers. Results 
(Figure 10) show that TMC when compared to the national hospital cohort had a higher 
percentage of Sickle cell patients with HbA1c tests (32% versus 11%). Ranking the linear 
unbiased predicted percentages of all the hospitals show that TMC ranks in the bottom 
25% quartile when compared to the other national hospitals with respect to inappropriate 
HbA1c orders.  However, TMC when compared to the national hospital cohort had a 
higher percentage of sickle cell patients with Fructosamine tests (11% versus 1%). This 
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high percentage of fructosamine encountered sickle cell patients in TMC is because 67% 
of those fructosamine encountered patients had both HbA1c tests and fructosamine. This 
correlates with the finding that fructosamine encounters have significantly increased after 
the year 2014. However, there was still a significantly higher number of sickle cell 
disease patients in TMC than in other national hospitals who had only HbA1c tests (24% 
versus 10%). This suggests that TMC being in the bottom quartile signifies that 
inappropriate HbA1c orders in sickle cell patients is a major quality concern in TMC 
when compared to its peers. This potential quality concern in TMC needs to be addressed 
with sustainable interventions in such a way that the physician is aware of the sickle cell 
condition of the patient before ordering HbA1c test. And the fact that, the use of a 
fructosamine test (glycated serum protein) in patients with sickle cell disease as a 
standalone test or in combination with HbA1c may be a reasonable option when an 
accurate HbA1c test cannot be obtained. 
 
  
Figure 10. Summary of the key findings in the Sickle cell population in other national 
hospitals (excluding TMC) compared to the Sickle cell population in TMC 
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Our study has several strengths. It is based on a large sample from multiple 
hospitals across US. This has an advantage over other local analyses, on the fact that this 
study can examine selected conditions and set a baseline characteristic for the quality 
concern. It also makes use of both ICD-9-CM and ICD-10-CM diagnosis codes which 
can efficiently capture the sickle cell disease patients. We used a Practice Based Evidence 
(PBE) approach which is an integral aspect of the Institute of Medicine (IOM) Learning 
Healthcare System strategy and can be performed by analyzing data generated during the 
delivery of the patient care (Ammerman et al., 2014). Often QI projects are selected in 
reaction to a recent adverse event. While this is frequently necessary after a critical issue, 
it may also result in failure to recognize deeper systemic quality gaps in which an 
organization is at significant variance from their peers. With respect to laboratory quality 
improvement, there is a significant opportunity to apply the practice based evidence 
strategy to the recognition of quality gaps, the selection of critical quality improvement 
projects and comparison with facilities with a high and low frequencies of the quality gap 
in order to inform interventions (Green, 2008). The proposed Generalized Linear Mixed 
Model (GLMM) in this study offered a few advantages. First, the linear unbiased 
predicted percentages from GLMM adjusted the bias due to covariates. Second, GLMMs 
were able to model the longitudinal structure of the data. Third, by including the hospital 
as a random variable in the mixed model, we were able to generalize the inference of the 
fixed effect to the population. Finally, the analytic pipeline developed in this study can be 
easily adopted to different measurements of outcome variables and address different 
research questions from Health Fact data source. 
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Conversely, this study has a number of significant limitations. First, this large 
national database of clinical data contains valuable yet heterogenous and difficult data in 
terms of high dimensionality. Additionally, analyzing EHR data is more challenging 
when compared to carefully controlled clinical trials as the data in the Health Facts data 
warehouse is completely reliant on billing codes with no way to verify its accuracy. 
Finally, fructosamine is rarely used in clinical practice and therefore the national data 
warehouse had very few encounters which can be compared with TMC. Other alternative 
tests such as glycated albumin and 1,5 anhydroglucitol did not have any encounters in the 
Sickle cell population in the EHR and was therefore not evaluated. 
Future studies, involving the diagnosis of diabetes mellitus in Sickle cell patients 
with HbA1c test would be challenging yet would result in a more precise dataset that 
provides more granularity. More granularity in the dataset could make connections in 
identifying incorrect diabetes diagnoses for sickle cell patients with inappropriate HbA1c 
tests and provide more details on possible mechanisms. Additionally, implementing a 
sustainable intervention in such a way that physicians are aware of this quality concern in 
ordering inappropriate HbA1c tests and then repeating the baseline measures could 
provide a way to identify if the quality concern has been alleviated. 
This project utilized the data from the HIPAA compliant, electronic health record 
(EHR) data in the Cerner Health Facts ™ (HF) data warehouse related to the clinical 
utility of the glycated Hemoglobin (HbA1c) test to monitor diabetes for sickle cell 
disease patients. Ranking the unbiased linear percentages estimated from the Generalized 
Linear Mixed Model of all the hospitals show that TMC ranks in the bottom 25% quartile 
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when compared to the other national hospitals. These findings indicate that inappropriate 
HbA1c orders in sickle cell patients is a potential quality concern in TMC which needs to 
be addressed with sustainable interventions so that overtreatment or under-treatment of 
the diabetic condition in sickle cell disease patients are avoided in order to improve 
patient and organizational outcome. 
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